Human monocytes/macrophages in the antitumour response of the host

Central-European Journal of Immunology

Volumn 28, Issue 2, 2003, Pages 88-103

  Szaflarska, Anna ^a,b   Siedlar, Maciej ^a   Zembala, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cytokines; Cytotoxic mediators; Immunotherapy; Monocytes macrophages; Tumour cells; Tumour infiltrating macrophages

Indexed keywords

CHEMOATTRACTANT; CISPLATIN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; GROWTH FACTOR; ICOSANOID; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTACYCLIN DERIVATIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANGIOGENESIS; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOSTASIS; CYTOTOXICITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE; MACROPHAGE; METASTASIS; MONOCYTE; PHENOTYPE; REVIEW; TUMOR GROWTH;

EID: 20644434905     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (277)

1. Mantovani A, Bottazzi B, Cololtta F, Sozzani S, Ruco L (1992): The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270.
2. Grace H, Wong W, Goeddel D: Tumour necrosis factor. In: Human monocytes. Ed. Zembala M, Asherson G: Academic Press, London 1989.
3. Krakauer T, Oppenheim J (1993): IL-1 and tumor necrosis factor-alpha each up-regulate both the expression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). J Immunol 150: 1205-1211.
4. C. Ishii N, Chiba M, Iizuka M, Horie Y, Masamune O (1994): Induction of HLA-DR antigen on human colonic epithelium by tumor necrosis factor-alpha and interferon-gamma. Scan J Gastroenterol 29: 903-907.
5. Menetrier-Caux C, Bain C, Favrot M, Due A, Blay J (1999): Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer 79: 119-130.
6. Pfizenmaier K, Scheurich P, Schluter C, Kronke M (1987): Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol 138: 975-980.
7. Watanabe Y, Jacob C (1991): Regulation of MHC class II antigen expression. Opposing effects of tumor necrosis factor-alpha on IFN-gamma-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell. J Immunol 146: 899-905.
8. Zembala M, Siedlar M, Ruggiero I, et al. (1994): The MHC class-II and CD44 molecules are involved in the induction of tumour necrosis factor (TNF) gene expression by human monocytes stimulated with tumour cells. Int J Cancer 56: 269-274.
9. Janicke R, Mannel D (1990): Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis. J Immunol 144: 1144-1150.
10. Mytar B, Wołoszyn M, Baj-Krzyworzeka M, et al.: Tumour cell-induced deactivation of human monocytes. (submited).
11. Siedlar M, Mytar B, Hyszko M, Zembala M (1999): Involvment of protein kinases in signalling for nitric oxide (NO) and tumour necrosis factor alpha (TNF) production by monocytes stimulated with colorectal DeTa cancer cells: the lack of evidence for the role of TNF in the regulation of NO production. Immunol Letters 65: 189-195.
12. Cohen M, Bereta M, Bereta J (1997): Effect of cytokines on tumour cell-endothelial interactions. Indian J Biochem Biophys 34: 199-204.
13. Vassali P (1992): The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452.
14. Lejeune F, Ruegg C, Lienard D (1998): Clinical applications of TNF-a in cancer. Curr Opin Immunol 10: 573-580.
15. Boldrini L, Calciani A, Samaritani E, et al. (2000): Tumour necrosis factor-α and transforming growth factor-β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. British J Cancer 83: 480-486.
16. Shau H (1988): Characteristic and mechanisms of neutrophil-mediated cytostasis induced by tumor necrosis factor. J Immunol 141: 234-240.
17. Rao V, Singh R, Delimont D, et al. (1999): Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol 14: 291-300.
18. Leber T, Balkwill F (1998): Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer 78: 724-732.
19. Macura-Biegun A (1998): The role of extracellular matrix in tumor progression. Central-European J Immunol 23: 8-14.
20. Rice G, Gimbrone M, Bevilacqua M (1988): Tumor cell-endothelial interactions: increased adhesion of human melanoma cells to activated vascular endothelium. Am J Pathol 133: 204-206.
21. Bereta M, Bereta J, Cohen S, Zaifert K, Cohen M (1991): Effect of inflammatory cytokines on the adherence of tumor cells to endothelium in a murine model. Cell Immunol 136: 263-267.
22. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W (1993): Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177: 1277-86
23. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W (1993): Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177:1277-1286.
24. Heriot A, Marriott J, Cookson S, Kumar D, Dalgleish A (2000): Reduction in cytokine production in colorectal cancer patients: association with stage and reversal resection. Br J Cancer 82: 1009-1012.
25. Zembala M, Mytar B, Wołoszyn M, et al. (1988): Monocyte TNF production in gastrointestinal cancer [letter]. Lancet 26: 1262.
26. Nakazaki H (1992): Preoperative and postoperative cytokines in patients with cancer. Cancer 70: 709-713.
27. Zhang G, Adachi I (1999): Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res 19: 1427-1232.
28. Socher S, Martinez D, Craig J, Kuhn J, Oliff A (1988): Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 80: 595-598.
29. Maltoni M, Fabbri L, Nanni O, et al. (1997): Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5: 130-135
30. Blakwill F, Mantovani A (2001): Inflammation and cancer: back to Virchow? Lancet 357: 539-542.
31. Sodhi A, Singh R, Singh S (1992) Effect of interferon-gamma priming on the activation of murine peritoneal macrophages to tumouricidal state by cisplatin, IL-1 and tumour necrosis factor (TNF): production of IL-1 and TNF. Clin Exp Immunol 88: 350-355.
32. Roberts A, O'Connel S, Ebert E (1993)tinal intraepithelial lymphocytes bind to colon cancer cells by HML-1 and CD11a. Cancer Res 53: 1608-1611.
33. Le J, Vilcek J (1987): Biology of disease. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 56: 234-248.
34. Onozaki K, Matsushima K, Aggrawal B, Oppenheim J (1985): Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 135: 3962-3968.
35. Ichinose Y, Tsao J, Fidler I (1988): Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF. Cancer Immunol Immunother 27: 7-12.
36. Raitano B, Korc M (1993): Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors. Cancer Res 53: 636-640.
37. Chasseing N, Trejo Y, Bordenave H, Zanoni L, Rumi L (1997): Intracytoplasmatic and extracellular interleukin-1 production by monocytes of lung and colorectal cancer patients. Acta Physiol Pharmacol Ther Latinoam 47: 147-156.
38. Sone S, Utsugi T, Tandon P, Yanagawa H, Okubo A, Ogura T (1990): Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. Cancer Immunol Immunother 30: 357-362.
39. Aggarwal B, Kohr W, Hass P, et al. (1985): Human tumor necrosis factor. Production, purification, and charakterization. J Biol Chem 260: 2345-2354.
40. Kutteh W, Kutteh C (1992): Quantitation of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 in the effusions of ovarian epithelial neoplasms. Am J Obstetrics Gynecology 167: 1864-1869.
41. Kabir S, Daar A (1995): Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 95: 207-212
42. Chopra V, Dinh T, Hannigan E. (1997): Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 123: 167-172.
43. Stefanovic V, Bogicevic M, Stamenic T, et al. (1994): Cytokine levels in patients with urinary tract cancer. Pathol Biol (Paris) 42: 842-846.
44. Matsuda T, Hirano T: IL-6. In: Cytokine References, vol. 1, Academic Press. London. 2001.
45. Hirano T (1991): Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int J Cell Cloning, 9: 166-184.
46. Kawano M, Hirano T, Matsuda T, et al. (1988): Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85.
47. Bataille R, Jourdan M, Zhang X, Klein B (1989): Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84: 2008-2011.
48. Barber M, Fearon K, Ross J (1999): Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 96: 83-87.
49. Okada S, Okusaka T, Ishii H, et al. (1998): Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 28: 12-15.
50. Chau G, Wu C, Lui W, et al. (2000): Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with repectable hepatocellular carcinoma. Ann Surg 231: 552-558.
51. Martin F, Santolaria F, Batista N, et al. (1999): Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11: 80-86.
52. Yano S, Sone S, Nishioka Y, et al. (1995): Differential effect of anti-inflammatory cytokines (IL-4, IL-10 and IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factor. J Leukoc Biol 57: 303-309.
53. Siegert A, Denkert C, Ledere A, Hauptmann S (1999): Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines. Immunology 98: 551-556.
54. Huang S, Xie K, Bucana C, Ullrich S, Bar-Eli M (1996): Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angigenesis. Clin Cancer Res 2: 1969-1979.
55. DeVita F, Orditura M, Galizia G, et al. (2000): Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep 7: 357-361.
56. Merendino R, Gangemi S, Misefari A, et al. (1999): Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett 68: 355-358.
57. Kucharzik T, Lugering N, Winde G, Domschke W, Stoll R (1997): Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exp Immunol 110:296-302.
58. Klimberg V, Kornbluth J, Cao Y, et al. (1996): Glutamine suppresses PGE2 synthesis and breast cancer growth. J Surg Res 63: 293-297.
59. Godwin I, Ceuppens J (1983): Regulation of the immune response by prostaglandins. J Clin, Immunol 3: 295-315.
60. Shmitt E, Hoehn P, Huels C, et al. (1994): T helper type I development of naive CD4+ T cells requires teh co-ordinate action of IL-12 and IFN-γ and is inhibited by TGF-β. Eur J Immunol 24: 793-798.
61. Germann T, Rude E (1995): Interleukin 12. Int Arch Allergy Immunol 108: 103-112.
62. Esche C, Shurin M, Lotze M: IL-12. In: Cytokine Reference, vol. 1. Academic Press. London. 2001.
63. Trinchieri G, Scott P (1994): The role of interleukin 12 in the immune response, disease and therapy. Immunology Today 15: 460-463.
64. Di Carlo E, Comes A, Basso S, et al. (1995): The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 165: 3111-3118.
65. Ha S, Lee C, Lee S, et al. (1999): A novel function of IL-12p40 as a chemotactic molecule for macrophages. J Immunol 163: 2902-2908.
66. Ha S, Lee S, Kim C, et al. (1998): Rapid recruitment of macrophages in interleukin-12-mediated tumour regression. Immunology 95: 156-163.
67. Haku T, Yanagawa H, Nabioullin R, et al. (1997): Interleukin-12-mediated killer activity in lung cancer patients. Cytokine 9: 846-852.
68. O'Hara R, Greenman J, MacDonald W, et al. (1998): Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleuki 10 production. Clin Cancer Res 4: 1943-1948.
69. Kovacs E (2000): Serum level of IL-12 and the production of IFN-gamma, IL-2, IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract. Biomed Pharmacother 54: 305-310.
70. Zeimet A, Widschwendter M, Knabbe C, et al.(1998): Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16: 1861-1868.
71. Heimdal J, Aarstad H, Olofsson I (2000): Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma. Laryngoscope 110: 402-407.
72. Fujiwara H, Hamaoka T (1996): Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 38, Suppl: 22-26.
73. Brunda M, Luistro L, Rumennik L, et al. (1996): Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38, Suppl: 16-21.
74. Mu J, Zou J, Yamamoto N, et al. (1995): Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55: 4404-4408.
75. Caminschi I, Venetsanakos E, Leong C, et al. (1998): Interleukin-12 induces an effective antitumor respnse in malignant mesothelioma. Am J Respir Cell Mol Biol 19: 738-746.
76. Mazzolini G, Qian C, Xie X, et al. (1999): Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 6: 514-522.
77. Gollob J, Mier J, Veenestra K, et al. (2000): Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6: 1678-1692.
78. Lebel-Binay S, Berger A, Zinzindohoue F, et al. (2000): Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 11: 15-26.
79. Hashimoto W, Osaki T, Okamura H, et al. (1999): Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 163: 583-589.
80. Coughlin C, Salhany K, Wysocka M, et al (1998): W: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angigenesis. J Clin Invest 101: 1441-1449.
81. Pages F, Berger A, Henglein B, et al. (1999): Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 84: 326-330.
82. Wiltschke C, Krainer M, Wagner A, et al. (1995): Influence of in vivo administration of CM-CSF and C-CSF on monocyte cytotoxicity. Exp Hematol 23: 402-406.
83. Ohsaka A, Saionji K, Kuwaki T, et al. (1995).: Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol 89: 465-472.
84. Comment in: Br J Haematol 91: 513-515.
85. Kacinski B (1995): CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 27: 79-85.
86. Chambers S, Kaciński B, Ivins C, Carcangiu M (1997): Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 3: 999-1007.
87. Tang R, Beuvon F, Ojeda M, et al. (1992): M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem 50: 350-356.
88. Scholl S, Pallud C, Beuvon F, et al. (1994): Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120-126.
89. Shinohara H, Yano S, Bucana C, Fidler I (2000): Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineerd expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells. J Immunol 164: 2728-2737.
90. Stuehr D, Nathan C (1989): Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169: 1543-1555.
91. Hibbs J, Taintor R, Vavrin Z, Rachlin E (1988): Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157: 87-94.
92. Patel R, McAndrews J, Sellak H, et al. (1999): Biological aspects of reactive nitrogen species. Biochim Biophys Acta 1411: 385-400.
93. Brown C (2001): Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochem Biophys Acta 1504: 46-57
94. Kurzawa H, Wysocka M, Aruga E, et al. (1998): Interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 58: 491-499.
95. Koblish H, Hunter C, Wysocka M, et al. (1998): Immune suppression by recombinant interleukin (rIL)-12 involves interferon (induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of sIL-12 vaccine adjuvant effect. J Exp Med 188: 1603-1610.
96. Allione A, Bernabei P, Bosticardo M, et al. (1999): Nitric oxide suppress human T lymphocyte proliferation through IFN-γ-dependent and IFN-γ-independent induction of apoptosis. J Immunol 163: 4182-4191.
97. Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J (1994): Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolisaccharide. Eur J Immunol 24: 435-439.
98. Albina J (1995): On the expression of nitric oxide synthase by human macrophages. Why no NO? J Leukoc Biol 58: 643-649.
99. Schneemann M, Schoedon G, Hofer S, et al. (1993): Nitric oxide synthase is not constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 167: 1358-1363.
100. Denis M (1994): Human monocytes/macrophages: NO or no NO? J Leukoc Biol 55: 682-684.
101. Siedlar M, Marcinkiewicz J, Zembala M (1995): MHC class I and class II determinants and some adhesion molecules are engaged in the regulation of nitric oxide production in vitro by human monocytes stimulated with colon carcinoma cells. Clin Immunol Immunopathol 77: 380-384.
102. Mills C, Shearer J, Evans R, Caldwell M (1992): Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 149: 2709-2714.
103. Takigawa M, Enomoto M, Nishide Y, et al. (1990): Tumor angiogenesis and polyamines: α-difluoromethyloornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in Vitro. Cancer Res 50: 4131-4138.
104. Kim P, Zamora R, Petrosko P, Billiar T (2001): The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 1: 1421-1441.
105. Torok N, Higuchi H, Bronk S, Gores G (2002): Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res 62: 1648-1653.
106. Kong G, Kim E, Kim W, et al. (2001): Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristic, and patient survival in pancreatic cancer. Int J Pancreatol 29: 133-140.
107. Chen G, Lee J, Chan U, et al. (2002): Increased apoptosis in infiltrating mononuclear cells of colorectal cancer. Arch Pathol Lab Med 126: 686-691.
108. Lanza F., Fietta A, Spisani S, et al. (1987): Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? J Clin Lab Immunol 22: 175-180.
109. Trulson A, Nilsson S, Brekkan E, Venge P (1994): Patients with renal cancer have a larger proportion of high-density blood monocytes with increased lucigeninenhanced chemiluminescence. Inflammation 18: 99-105.
110. Mytar B, Siedlar M, Wołoszyn M, et al. (1999): Induction of reactive oxygen intermediates in human monocytes by tumour cells and their role in spontaneous monocyte cytotoxicity. Br J Cancer 79: 737-743.
111. Kono K, Salazar-Onfray F, Petersson M, et al. (1996): Hydrogen peroxide secreted by tumor-derived macrophages downmodulates signal-transducing zeta molecules and inhibits tumor-specific T-cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 26: 1308-1313.
112. Mytar B, Siedlar M, Woloszyn M, Colizzi V, Zembala M (2001): Cross-talk between human monocytes and cancer cells during reactive oxygen intermediates generation: the essential role of hyaluronian. Int J Cancer 94: 727-732.
113. Kurland J, Bockman R, Broxmeyer H, Moore M (1978): Limitation of excessive myelopoesis by the intrinsic modulation of macrophage-derived prostaglandin E. Science 199: 552-555.
114. Nara K, Odagiri H, Fujii M, et al. (1987): Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma. Cancer Immunol Immunother 25: 126-132.
115. Bennet A, Carroll M, Stamford I, et al. (1992): Prostaglandins and human lung carcinomas. Br J Cancer 46: 888-893.
116. Karmali R, Wustrow T, Thaler H, Strong E (1984): Prostaglandins in carcinomas of the head and neck. Cancer Lett 22: 333-336.
117. Yang C, Meng C (1994): Regulation of PG synthase by EGF and PDGF in human oral, breast, stomach and fibrosarcoma cancer cell lines. J Dent Res 73: 1407-1415.
118. Braun D, Ahn M, Harris J, et al. (1993): Sensitivity of tumoricidal function oin macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism. Cancer Res 53: 3362-3368.
119. Tripp C, Needleman P (1987): Regulation of macrophage arachidonic acid metabolism during the immune response. Adv Prostaglandin Thromboxane Leukot Res 17B: 1085-1090.
120. Ben-Efraim S, Bonta I (1994): Modulation of antitumour activity of macrophages by regulation od eicosanoids and cytokine production. Int J Immunopharmac 16: 397-399.
121. Van Damme J, Proost P, Lenaerts J, Opdenakker G (1992): Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 176: 59-65.
122. Valkovic T, Lucin K, Krstulja M, et al. (1998): Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194: 335-340.
123. Ueno T, Masakazu T, Saji H, et al. (2000): Significance of macrophage chemo-attractant protein-1 on macrophage recruitment, angiogenesis and survival in human breast cancer. Clin Cancer Res 6: 3282-3289.
124. Jiang J, Beller D, Frendl G, Graves D (1992): Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148: 2423-2428.
125. Hefler L, Tempfer C, Heinze G, et al. (1999): Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81: 855-859.
126. Zhang L, Khayat A, Cheng H, Graves D (1997): The pattern of monocyte recruitment in tumors is modulated by MCP-1 expression and influences the rate of tumor growth. Lab Invest 76: 579-590.
127. Tan I, Drexhage H, Scheper R, et al. (1986): Defective monocyte chemotaxis in patients with head and neck cancer. Restoration after treatment. Arch Otolaryngol Head Neck Surg 112: 541-544.
128. Nielsen H, Bennedsen J, Dombernowsky P (1982): Normalization of defective monocyte chemotaxis during chemotherapy in patients with small cell anaplastic carcinoma of the lung. Cancer Immunol Immunother 14: 13-15.
129. Yamane T, Sakita M, Kasuga M, et al. (1981): Monocyte count, monocyte chemotaxis and chemotactic factor inactivator in gastric cancer patient. Jpn J Surg 11: 422-427.
130. Snyderman R, Meadows L, Holder W, Wells S (1978): Abnormal monocyte chemotaxis in patients with breast cancer: evidence for a tumor-mediated effect. J Natl Cancer Inst 60: 737-740.
131. Hausman M, Brosman S, Snyderman R, et al. (1975): Defective monocyte function in patients with genitourinary carcinoma. J Natl Cancer Inst 55: 1047-1054.
132. Snyderman R, Seigler H, Meadows L (1977): Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. J Natl Cancer Inst, 58: 37-41.
133. Sica A, Saccani A, Bottazzi B, et al. (2000): Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 164: 733-738.
134. Arenberg D, Keane M, DiGiovine B, et al. (2000): Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother 49: 63-70.
135. Gebhard B, Gnant M, Schutz G, et al. (2000): Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res 20: 4599-4604.
136. Mantovani A, Jerrells T, Dean J, Herberman R (1979): Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer 23: 18-27.
137. Davies B, Edwards S (1992): Interactions between human monocytes and tumour cells. Br J Cancer 66: 463-469.
138. Gerrard T, Terz J, Kaplan A (1980): Cytotoxicity to tumour cells of monocytes from normal individuals and cancer patients. Int J Cancer 26: 585-593.
139. Siziopikou K, Harris J, Casey L, et al. (1991): Impaired tumoricidal function of alveolar macrophages from patients with non-small cell lung cancer. Cancer 68: 1035-1044.
140. Barna B, Rogers L, Thomassen M, et al. (1991): Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol Immunother 33: 314-318.
141. Murali P, Somasundaram R, Chiplunkar S, et al. (1989): Monocyte/macrophage functions in patients with squamous cell carcinoma of the oral cavity. J Oral Pathol Med 18: 539-543.
142. Galligioni E, Quaia M, Spada A, et al. (1993): Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells. Int J Cancer 55: 380-385.
143. Jhaver K, De A, Advani S, Nadkarni J (1991): Production of interleukin-1 and tumour necrosis factor in non-Hodgkin' lymphoma patients. Cancer Immunol Immunother 34: 123-127.
144. Mace K, Ehrke M, Hori K, et al. (1988): Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res 48: 5427-5432.
145. Fisher D, Rubinstein M (1986): Human monocytes tumoricidal activity: the role of interferon-gamma and bacterial lipopolysaccharide in its stimulation, preservation and decay. Immunobiology 172: 110-119.
146. Nishimura Y, Higashi N, Tsuji T, et al. (1992): Activation of human monocytes by interleukin-2 and various cytokines. J Immunother 12: 90-97.
147. Bosco M, Pulkki K, Rowe T, et al. (1995): IL-4 inhibits IL-2 induced tumoricidal activity and secretory functions of human monocytes. Modulation of IL-2 receptor beta gamma chain expression. J Immunol 155: 1411-1419.
148. Grabstein K, Urdal D, Tushinski R, et al. (1986): Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506-508.
149. Howard A, Erickson K (1995): The induction and augmentation of macrophage tumouricidal responses by plated-activating factor. Cell Immunol 164: 105-112.
150. Perri R, Vercellotti G, McCarthy J, et al. (1985): Laminin selectively enhances monocyte-macrophage-mediated tumoricidal activity. J Lab Clin Med 105: 30-35.
151. McLachlan J, Serkin C, Morrey K, Bakouche O (1995): Antitumoral properties of aged human monocytes. J Immunol 154: 832-843.
152. Peri G, Polentarutti N, Sessa C, et al. (1981): Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin. Int J Cancer 28: 143-152
153. Nio Y, Zighelboim J, Berek J, Bonavida B (1990): Cycliheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemother Pharmacol 26: 1-8.
154. Mantovani A: Cytotoxic killing of tumour cells by monocytes. In: Human monocytes. Ed. Zembala M, Asherson G: Academic Press, London, 1989, 303.
155. Utsugi T, Schroit A, Connor J, et al. (1991): Elevated expression of phosphatidylserine in outer membrane leaflet of human tumour cells and recognition by activated human blood monocytes. Cancer Res 61: 241-248.
156. Tripathi A, Taplits M, Puri J, Hoffman T (1991): Down-regulation of surface FcRI and decrease in antibody-dependent cellular cytotoxicity of cultured monocytes. J Immunol 146: 1309-1315.
157. Fanger M, Shen L, Graziano R, Guyre M (1989): Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 10: 92-99.
158. Hellstrom I, Garrigues U, Lavie E, Hellstrom K (1988): Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Res 48: 624-627.
159. Moutsatsos I, Davis J, Wanng J (1986): Endogenous lectins from cultured cells: subcellular localisation of carbohydrate-binding protein 35 in 3T3 fibroblasts. J Cell Biol 102: 477-483.
160. Salminen E, Kankuri M, Nuutila J, et al. (2001): Modulation of IgG and complement receptor expression of phagocytes in kidney cancer patients during treatment with interferon-alpha. Anticancer Res 21: 2049-2055
161. Uracz W, Pituch-Noworolska A, Zembala M, et al. (1982): "Activated" monocytes in gastric cancer patients. An increased Fc receptor expression, antibody dependent cellular cytotoxicity and NBT reduction. J Cancer Res Clin Oncol 104: 181-184.
162. Vena G, Angelini G, D'Ovidio R, et al. (1983): Monocyte Fc-IgG receptors expression and soluble suppressor factor in skin squamous cell carcinomas. Acta Derm Venereol 63: 507-512.
163. Gebhard B, Gant M, Schutz G, et al. (2000): Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res 20: 4599-4604.
164. Mytar B, Baran J, Gawlicka M, et al. (2002): Immunophenotypic changes and induction of apoptosis of monocytes and tumour cells during their interactions in vitro. Anticancer Research 22: 2789-2796.
165. Zembala M, Buckle A: Monocytes in malignant disease. In: Human monocytes.Ed. Zembala M, Asherson G: Academic Press, London 1989, 514-528.
166. + blood monocytes exhibits features of tissue macrophages. Eur J Immunol 23: 2053-2056.
167. Frankenberg M, Sternsdorf T, Pechumer H, et al. (1996): Differential cytokine expression in human blood monocyte subpopulation: a polymerase chain reaction analysis. Blood 87: 373-379.
168. + blood monocytes is expanded in sepsis patients. Blood 82: 3170-3175.
169. Thomas R, Lipsky P (1994): Human peripheral blood dendritic cell subsets. Isolation and characterisation of precursor and mature antigen presenting cells. J Immunol 153: 4016-4028.
170. + monocytes. Immunobiol 202: 11-17.
171. Locher C, Vanham G, Kestens L, et al. (1994): Expression patterns of Fc(receptors, HLA-DR and selected adhesion monlecules on monocytes from normal and HIV-infected individuals. Cli Exp Immunol 98: 115-121.
172. + monocytes in critically ill cardiac surgery patients. Inflammation 22: 367-372.
173. Saleh M, Goldman S, LoBugilo A, et al. (1995): CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85: 2910-2917.
174. Schmid I, Baldwin G, Jacobs E, et al. (1995): Alternations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF. Cytometry 22: 103-110.
175. Beller D, Springer T, Schreiber R (1982): Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med 56: 1000-1009.
176. Shang X, Issekutz A (1998): Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) -2 (CD102) to human monocyte migration through endothelium and connective tissue barriers. Eur J Immunol 28: 1970-1979.
177. Allen C, Hogg N (1987): Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 78: 465-470.
178. Zhang L, Yoshimura T, Graves D (1997): Antibody to Mac-1 or monocyte
179. Jiang Y, Zhu J, Luscinskas F, Graves D (1994): MCP-1-stimulated monocyte attachment to laminin is mediated by beta 2-integrins. Am J Physiol 267: 1112-1118.
180. Jiang Y, Beller D, Frendl G, Graves D (1992): Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148: 2423-2428.
181. Salminen E, Kankuri M, Nuutila J, et al. (2001): Modulation of IgG and complement receptor expression of phagocytes in kidney cancer patients during treatment with interferon-alpha. Anticancer Res 21: 2049-2055.
182. Carlos T, Harlan J (1990): Membrane proteins involved in phagocyte adherence to endothelium. Immunol-Rev 114: 5-28.
183. Chuluyan H, Lang B, Issekutz A (2000): Differential mechanisms of neutrophil and monocytes adhesion on neuroblastoma cells: CD18 and VLA-4 integrins mediate adhesion to SK-N-SH, but not to SK-N-MC cell line. J Neurosci Res 60: 649-655.
184. Zembala M, Mytar B, Ruggiero I, et al. (1982): Suppressor cells and survival of patients with advanced gastric patients. J Natl Cancer Inst 70: 223-228.
185. Jerrells T, Dean J, Richardson G, et al. (1979): Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer patients. Int J Cancer 23: 768-772.
186. Mytar B, Zembala M, Uracz W, Czupryna A (1982): Cytostatic activity on tumour cells of monocytes from patients with gastrointestinal cancer. Cancer Immunol Immunother 13: 190-193.
187. Kiertscher S, Luo J, Dubinett S, Roth M (2000): Tumors promote alterd maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164: 1269-1276.
188. Ladisch S, Li R, Olson E (1994): Ceramide structure predicts tumor gangliside immunosuppressive activity. Proc Natl Acad Sci USA, 91: 1974-1978.
189. Olshefski R, Ladisch S (1996): Intercellular transfer of shed tumor cell gangliosides. FEBS Letters 386: 11-14.
190. van Ravenswaay Claasen H, Kluin P, Fleuren G (1992): Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 67: 166-174.
191. Leek RD, Lewis CE, Whitehouse R, et al. (1996): Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629.
192. Lewis C, Leek R, Harris A, McGee J (1995): Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 57: 747-751.
193. Tromp S, oude Egbrink M, Dings R, et al. (1999): Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 12: 671-676.
194. Toomey D, Harmey J, Condron C, et al. (1999): Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 28: 29-41.
195. Gottlinger H, Rieber P, Gokel J, et al. (1985): Infiltrating mononuclear cells in human breast carcinoma: predominance of T4+ monocytic cells in the tumor stroma. Int J Cancer 35: 199-280.
196. Broker E, Zwadlo G, Holzmann B, et al. (1988) Int J Cancer 41: 562-567.
197. Loercher A, Nash M, Kavanagh J, et al. (1999): Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163: 6251-6260.
198. Allen A, Hogg N (1987): Association of colorectal tumor epithelium expressing HLA-D/DR with CD8 positive T-cells and mononuclear phagocytes. Cancer Res 47: 2919-2923.
199. Chaux P, Moutet M, Faivre J, et al. (1996): Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74: 975-983.
200. Ropponen K, Eskelinen M, Lipponen P, et al. (1997): Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324.
201. Yanagawa H, Takeuchi E, Suzuki Y, et al. (1999): Production of interleukin-10 by alveolar macrophages form lung cancer patients. Respir Med 93: 666-671.
202. Doi C, Noguchi Y, Marat D, et al. (1999): Expression of nitric oxide synthase in gastric cancer. Cancer Lett 144: 161-167.
203. Thomsen L, Miles D, Happerfield L, et al. (1995): Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41-44.
204. Vakkala M, Kahlos K, Lakari E, et al. (2000): Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 6: 2408-2416.
205. Naylor M, Malik S, Stamp G, et al. (1990): In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 26: 1027-1030.
206. Naylor M, Stamp G, Balkwill F (1990): Demonstration of mRNA for tumor necrosis factor and other cytokines in human colorectal cancer. Cancer Res 50: 4436-4440.
207. Erroi A, Simoni M, Chiaffarino F, et al. (1989): IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer 44: 795-801.
208. Mantovani A, Dean J, Jerrells T, Herberman R (1980): Augmentation of tumoricidal activity of human monocytes and macrophages by lymphokines. Int J Cancer 25: 691-699.
209. Van Netten J, Ashamead B, Cavers D (1992): Macrophages and their putative significance in breast cancer. Br J Cancer 66: 220-221.
210. Kleiner D, Steuer-Stevenson W (1999): Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43, Suppl: 42-51.
211. Gorrin-Rivas MJ, Arii S, Mori A, et al (2000): Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg 231: 67-73.
212. Patterson BC, Sang QA (1997): Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/typ IV collagenase (MMP-9). J Biol Chem 272: 28823-28825.
213. Swallow C, Murray M, Guillem J (1996): Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes. Clin Exp Metastasis 14: 3-11.
214. Jiang Y, Goldberg I, Shi Y (2002): Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 28: 2245-2252.
215. Chang C, Werb Z (2001): The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11: 37-43.
216. Mizoi T, Ohtani H, Suzuki Y, et al. (1995): Intercellular adhesion molecule-1 expression by macrophages in human gastrointestinal carcinoma: possible roles as host immune/inflammatory reaction. Pathol Int 45: 565-572.
217. Stauder R, Greil R, Schulz T, et al. (1989): Expression of leukocyte function-associated antigen-1 and 7F7 antigen, an adhesion molecule related to intracellular adhesion molecule-1 (ICAM-1) in non-Hodkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour. Clin Exp Immunol 77: 234-238.
218. Johnson J, Stade B, Holzmann B, et al. (1989): De novo expression of intracellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86: 641-644.
219. Vogetseder W, Feichtinger H, Schulz T, et al. (1989): Expression of 7F7 antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int J Cancer 43: 768-773.
220. Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S (1990): Expression of intercellular adhesion molecule-1 (ICAM-1) on renal cell cancer: possible significance in host immune responses. Int J Cancer 46: 1001-1006.
221. Schardt C, Heymanns J, Schardt C, et al. (1993): Differential expression of the intercellular adhesion molecule-1 (ICAM-1) in lung cancer cell lines of various histological types. Eur J Cancer 29: 2250-2255.
222. Hutchins D, Steel CM (1994): Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer, 58: 80-84.
223. Morandin R, Boeynaems J, Duhant X, et al. (1999): SODs are involved in the regulation of ICAM-1 expression in human melanoma and endothelial cells. Cell Biol Mol 45: 1053-1063.
224. Hutchins D, Steel CM (1994): Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 58: 808-814.
225. McBride W, Bard J (1979): Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte mediated cytolysis. J Exp Med 149: 507-515.
226. Jonjic N, Alberti S, Bernasconi S, et al. (1992): Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer. Eur J Immunol 22: 2255-2260.
227. Nagaoka H, Iino Y, Takei H, Morishita Y (1998): Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 13: 449-454.
228. Senger D, Van de Water L, Brown L, et al. (1993): Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324.
229. Harmey J, Dimitriadis E, Kay E, et al. (1998): Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transformigf growth factor β-1. Ann Surg Oncol 5: 271-278.
230. Leek R, Hunt N, Landres R, et al. (2000): Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190: 430-436.
231. Shibuya M, Luo J, Toyoda M, Yamaguchi S (1999): Involvement of VEGF ana its receptors in ascites tumor formation. Cancer Chemother Pharmacol 43 Suppl: 72-77.
232. Clauss M, Gerlach M, Gerlach H, et al. (1990): Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172: 1535-1545.
233. Strieter R, Polverini P, Arenberg D, Kunkel S (1995): The role of CXC chemokines as regulators of angiogenesis. Shock 4: 155-160.
234. Strieter R, Kunkel S, Arenberg D, et al. (1995): Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 210: 51-57.
235. Salcedo R, Ponce M, Young H, et al. (2000): Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96: 34-40.
236. Mahadevan V, Hart J (1990): Metastases and angiogenesis. Acta Oncol 29: 319-331.
237. West D, Hapson I, Arnold F, Kumar S (1995): Angiogenesis induced by degradation products of hyaluronic acid. Science 228: 1324-1326.
238. Hildenbrand R, Dilger I, Stutte H (1995): Urokinase and macrophages in tumour angiogenesis. Br J Cancer 72: 818-823.
239. Pyke C, Kristensen P, Ralfkiaer E, et al. (1991): Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067.
240. Mahadevan V, Hart J (1990): Metastases and angiogenesis. Acta Oncol 29: 97-103.
241. Zuk J, Walker R (1987): Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Pathol 152: 275-285.
242. Barbera-Guillem E, May K, Nyhus J, Nelson M (1999): Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1: 453-460.
243. Swallow C, Murray M, Guillem J (1996): Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes. Clin Exp Metastasis 14: 3-11.
244. Ito A, Handa K, Withers D, Satoh M, Hakomori S (2001): Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett 504: 82-6.
245. Lwaleed BA, Bass PS, Cooper AJ (2001): The biology and tumour-related properties of monocyte tissue factor. J Pathol 193: 3-12.
246. Bingle L, Brown N, Lewis C (2002): The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
247. Edwards R, Rickles F, Cronlund M (1981): Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tisue factor generation. J Lab Clin Med 98: 917-928.
248. Lwaleed B, Chisholm M, Francis J (1999): The significance of measuring monocyte tissue factor in patients with breast and colorectal cancer. Br J Cancer 80: 279-285.
249. Dano K, Andreasen P, Grondhal-Hansen J, et al. (1985): Plasminogen activators. Tissue degradation and cancer. Adv Cancer Res 44: 139-266.
250. Dvorak H (1986): Tumours: wounds that do not heal. N Engl J Med 315: 161-165.
251. Lipponen P (1996): Expression of cathepsin D in transitional cell bladder tumours. J Pathol 178: 59-64.
252. Lah T, Kaiman E, Najjar D, et al. (2000): Cells producing cathepsins B, D and L in human breast carcinoma and their association with prognosis. Hum Pathol 31: 149-160.
253. Spotl L, Sarti A, Dierich M, Most J (1995): Cell membrane labeling with fluorescent dyes for the demonstration of cytokine-induced fusion between monocytes and tumor cells. Cytometry 21: 160-169.
254. Larizza L, Schirrmacher V, Graf L, et al. (1984): Suggestive evidence that the highly metastatic variant Esb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int J Cancer 34: 699-707.
255. Teitelbaum S, Stewart C, Kahn A (1979): Rodent peritoneal macrophages as bone resorbing cells. Calcif Tissue Int 27: 255-261.
256. Yonemura Y, Endo Y, Yamaguchi T, et al. (1996): Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int J Oncology 8: 795-802.
257. Hagiwara A, Takahashi T, Sawai K, et al. (1993): Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 53: 687-692.
258. Rosenberg S, Lotze M, Muul L, Chang A, Avis F (1987): Progress report on treatment of 157 patients with advanced cancer using LAK cells and IL2 or IL2 alone. New Engl Med 316: 889-897.
259. Stevenson HC: Adoptive cellular immunotherapy of cancer. Marcel Dekker, New York, 1989.
260. Bartholeyns J, Lopez M, Andreesen R (1991): Adoptive immunotherapy of solid tumors with activated macrophages; experimental and clinical results. Anticancer Res 11: 1201-1204
261. Fidler I, Jessup J, Fogler W, et al. (1986): Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 46: 994-998.
262. Chokri M, Lopez M, Oleron C, et al. (1992): Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3. Anticancer Res 12: 2257-2260.
263. Hennemann B, Beckman G, Eichelmann A, et al. (1998): Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon ? and lipopolisaccharide. Cancer Immunol Immunother 45: 250-256.
264. Chokri M, Girard A, Borrelly M, et al. (1992): Adoptive immunotherapy with bispecific antibodies: targeting through macrophages. Res Immunol 143: 95-99.
265. Stevenson H, Keenan A, Woodhouse C, et al. (1987): Fate of IFN-gamma activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinoma. Cancer Res 47: 6100-6103.
266. Andreesen R, Scheibenbogen C, Brugger W, et al. (1990): Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating monocytes: a new approach to cancer immunotherapy. Cancer Res 50: 7450-7456.
267. Faradji A, Bohbot A, Schmitt M, et al. (1991): Phase I trial of IV infusion of ex vivo activated blood-derived macrophages in patients with non-small cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 33: 319-326.
268. Lopez M, Fechtenbaum J, David B, et al. (1992): Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 11: 209-217.
269. Anderson C (1992): Gene therapy researcher under fire over controversial cancer trials. Nature 360: 399-403.
270. Walder S, Haynes H, Beitler J, et al. (1996): Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 78: 30-34.
271. Wiesel M, Faradji A, Grunebaum L, et al. (1992): Hemostatic changes in human adoptive immunotherapy with activated blood monocytes or derived macrophages. Ann Hematol 65: 778-782.
272. Allavena P, Grandi M, D'Incalci M, et al. (1987): Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 40: 104-107.
273. Allavena P, Damia G, Colombo T, et al. (1989): Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agent. Cell Immunol 120: 250-258.
274. Bartholeyns J, Lopez M (1994): Immune control of neoplasia by adoptive transfer of macrophages: potentiality for antigen presentation and gene transfer. Anticancer Res 14: 2673-2676.
275. Lei H, Ju D, Yu Y, et al. (2000): Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-gamma. Gene Ther 7: 707-713.
276. Bonig H, Korholz D, Lex C, et al. (2000): Monocyte deactivation and its reversal in a patient with chemotherapy-induced leukopenia and severe systemic infection. Med. Pediatr Oncol 34: 39-42.
277. Griffiths L, Binley K, Iqball S, et al. (2000): The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 7: 255-262.